<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03358576</url>
  </required_header>
  <id_info>
    <org_study_id>IT001-303</org_study_id>
    <nct_id>NCT03358576</nct_id>
  </id_info>
  <brief_title>Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)</brief_title>
  <official_title>Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of Efiicacy, Tolerability &amp; Safety of Sulopenem &amp; Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro-metronidazole for Treatment of cIAI in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iterum Therapeutics, International Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iterum Therapeutics, International Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, Phase 3, randomized, multi-center, double-blind study of the efficacy,&#xD;
      tolerability and safety of sulopenem followed by sulopenem-etzadroxil/probenecid versus&#xD;
      ertapenem followed by ciprofloxacin-metronidazole for treatment of complicated&#xD;
      intra-abdominal infections in adults.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Actual">October 2, 2019</completion_date>
  <primary_completion_date type="Actual">October 2, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Clinical Success</measure>
    <time_frame>Day 28 +/- 1 day</time_frame>
    <description>Clinical response is defined as resolution in signs and symptoms of the index infection and no new symptoms, without the need for additional antibiotics or interventions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Success</measure>
    <time_frame>Day 11-14 +/- 1 day</time_frame>
    <description>Clinical response is defined as resolution in signs and symptoms of the index infection and no new symptoms, without the need for additional antibiotics or interventions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">674</enrollment>
  <condition>Intra Abdominal Infections</condition>
  <arm_group>
    <arm_group_label>Sulopenem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sulopenem 1000 mg IV once daily for at least 5 days, followed by Sulopenem-Etzadroxil/Probenecid 500 mg PO twice daily to complete 7-10 days of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertapenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ertapenem 1000 mg IV once daily for at least 5 days, followed by ciprofloxacin 500 mg PO twice daily along with metronidazole 500 mg PO four times daily. If patient is found to have causative pathogens that are resistant to ciprofloxacin they will receive amoxicillin-clavulanate 875 mg PO twice daily instead</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertapenem</intervention_name>
    <description>Antibiotic for complicated intra-abdominal infection</description>
    <arm_group_label>Ertapenem</arm_group_label>
    <other_name>Invanz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulopenem-Etzadroxil/Probenecid</intervention_name>
    <description>Antibiotic for complicated intra-abdominal infection</description>
    <arm_group_label>Sulopenem</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Antibiotic for complicated intra-abdominal infection</description>
    <arm_group_label>Ertapenem</arm_group_label>
    <other_name>Cipro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Antibiotic for complicated intra-abdominal infection</description>
    <arm_group_label>Ertapenem</arm_group_label>
    <other_name>Flagyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin-Clavulanate</intervention_name>
    <description>Antibiotic for complicated intra-abdominal infection</description>
    <arm_group_label>Ertapenem</arm_group_label>
    <other_name>Augmentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulopenem</intervention_name>
    <description>Antibiotic for complicated intra-abdominal infection</description>
    <arm_group_label>Sulopenem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient or the patient's legally acceptable representative able to provide a signed&#xD;
             written informed consent prior to any study-specific procedures.&#xD;
&#xD;
          2. Adult patients ≥18 years of age&#xD;
&#xD;
          3. EITHER:&#xD;
&#xD;
             a. Intra-operative/post-operative enrollment with visual confirmation (presence of pus&#xD;
             within the abdominal cavity) of an intra-abdominal infection associated with&#xD;
             peritonitis including at least 1 of the following diagnosed during the surgical&#xD;
             intervention: i. Cholecystitis with gangrenous rupture or perforation or progression&#xD;
             of the infection beyond the gallbladder wall ii. Diverticular disease with perforation&#xD;
             or abscess iii. Appendiceal perforation or peri-appendiceal abscess iv. Traumatic&#xD;
             perforation of the intestines, only if operated on &gt;12 hours after perforation occurs&#xD;
             v. Secondary peritonitis (but not spontaneous bacterial peritonitis associated with&#xD;
             cirrhosis and chronic ascites) vi. Intra-abdominal abscess (including of liver or&#xD;
             spleen provided that there was extension beyond the organ with evidence of&#xD;
             intraperitoneal involvement).&#xD;
&#xD;
             OR:&#xD;
&#xD;
             b. Pre-operative enrollment where one of the following surgical procedures are planned&#xD;
             within 24 hours prior to the first dose of study drug: i. Open laparotomy,&#xD;
             percutaneous drainage of an intra-abdominal abscess, or laparoscopic surgery.&#xD;
&#xD;
          4. Evidence of systemic inflammatory indicators, with at least one of the following:&#xD;
&#xD;
             i. Fever (defined as body temperature &gt;38°C) or hypothermia with a core body&#xD;
             temperature &lt;35°C ii. Elevated white blood cell count (&gt;12,000 cells/mm3) iii. Drop in&#xD;
             blood pressure (systolic BP must be &lt;90 mmHg without pressor support) iv. Increased&#xD;
             heart rate (&gt;90 bpm) and respiratory rate (&gt;20 breaths/min) v. Hypoxia (oxygen&#xD;
             saturation ≤90 percent on room air)&#xD;
&#xD;
          5. Physical findings or symptoms consistent with intra-abdominal infection, with at least&#xD;
             one of the following:&#xD;
&#xD;
             i. Abdominal pain and/or tenderness, with or without rebound ii. Localized or diffuse&#xD;
             abdominal wall rigidity iii. Abdominal mass iv. Nausea/vomiting v. Altered Mental&#xD;
             Status&#xD;
&#xD;
          6. Specimen/s from the surgical intervention were sent for culture.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient diagnosed with traumatic bowel perforation undergoing surgery within 12 hours;&#xD;
             perforation of gastroduodenal ulcers undergoing surgery within 24 hours. Other&#xD;
             intra-abdominal processes in which the primary etiology was not likely to be&#xD;
             infectious.&#xD;
&#xD;
          2. Patient has abdominal wall abscess or bowel obstruction without perforation or&#xD;
             ischemic bowel without perforation.&#xD;
&#xD;
          3. Patient has simple cholecystitis or gangrenous cholecystitis without rupture, or&#xD;
             simple appendicitis, or acute suppurative cholangitis; or infected necrotizing&#xD;
             pancreatitis or pancreatic abscess.&#xD;
&#xD;
          4. Patient whose surgery included staged abdominal repair, or &quot;open abdomen&quot; technique,&#xD;
             or marsupialization.&#xD;
&#xD;
          5. Patient known at study entry to have a complicated intra-abdominal infection caused by&#xD;
             pathogens resistant to the study antimicrobial agents.&#xD;
&#xD;
          6. Patient needed effective concomitant systemic antibacterials (oral, IV, or&#xD;
             intramuscular) or antifungals in addition to those designated in the 2 study groups,&#xD;
             except vancomycin, linezolid, or daptomycin if started for known or suspected&#xD;
             methicillin-resistant Staphylococcus aureus (MRSA) or Enterococcus spp. as per&#xD;
             clinical study protocol (CSP).&#xD;
&#xD;
          7. Patient has perinephric infections or an indwelling peritoneal dialysis catheter.&#xD;
&#xD;
          8. Patient has suspected intra-abdominal infections due to fungus, parasites (e.g.,&#xD;
             amoebic liver abscess), virus, or tuberculosis.&#xD;
&#xD;
          9. Patient has a known history of serious allergy, hypersensitivity or any serious&#xD;
             reaction to carbapenem antibiotics, or to other β-lactam antibiotics&#xD;
&#xD;
         10. Patient known to have any of the following laboratory values as defined below:&#xD;
&#xD;
               1. Hematocrit &lt;25% or hemoglobin &lt;8 g/dL&#xD;
&#xD;
               2. Absolute neutrophil count &lt;1000/mm3&#xD;
&#xD;
               3. Platelet count &lt;75,000/mm3&#xD;
&#xD;
               4. Bilirubin &gt;3 x the upper limit of normal (ULN), unless isolated&#xD;
                  hyperbilirubinemia was directly related to the acute infection or known Gilbert's&#xD;
                  disease&#xD;
&#xD;
               5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;3 x ULN&#xD;
                  values at Screening. Patients with elevations of AST and/or ALT up to 5 x ULN&#xD;
                  will be eligible if these elevations are acute and directly related to the&#xD;
                  infectious process being treated. This must be documented&#xD;
&#xD;
               6. Alkaline phosphatase (ALP) &gt;3 x ULN. Patients with values &gt;3.0 x ULN and &lt;5.0 x&#xD;
                  ULN are eligible if this value is acute and directly related to the infectious&#xD;
                  process being treated. This must be documented.&#xD;
&#xD;
               7. Estimated creeatinine clearance &lt;50 mL/min&#xD;
&#xD;
         11. Patient has a body mass index &gt;45 kg/m2.&#xD;
&#xD;
         12. Patient has APACHE II score &gt;30.&#xD;
&#xD;
         13. Patient considered unlikely to survive the 4-week study period or has a rapidly&#xD;
             progressive or terminal illness, including septic shock that was associated with a&#xD;
             high risk of mortality.&#xD;
&#xD;
         14. Patient unlikely to respond to 10-14 days of treatment with antibiotics.&#xD;
&#xD;
         15. Patient received systemic antibacterial agents within the 72-hour period prior to&#xD;
             study entry, unless either of the following pertained:&#xD;
&#xD;
             a. Patient has a new infection (not considered a treatment failure) and both of the&#xD;
             following were met: i. Patient received no more than 24 hours of total prior&#xD;
             antibiotic therapy ii. Patient received ≤1 dose of a treatment regimen&#xD;
             post-operatively and antibiotics were not received more than 6 hours post-procedure.&#xD;
&#xD;
             b. Patient considered to have failed the previous treatment regimen i.e.,&#xD;
             pre-operative treatment of any duration with non-study systemic antimicrobial therapy&#xD;
             for peritonitis or abscess permitted provided that all of the following are met: i.&#xD;
             The treatment regimen had been administered for at least 72 hours and was judged to&#xD;
             have been inadequate ii. The patient had an operative intervention that was just&#xD;
             completed or was intended no more than 24 hours after study entry iii. Findings of&#xD;
             infection were documented at surgery iv. Specimens for bacterial cultures and&#xD;
             susceptibility testing were taken at operative intervention v. No further non-study&#xD;
             antibacterials were administered after randomization.&#xD;
&#xD;
         16. Patient has a concurrent infection that may interfere with the evaluation of response&#xD;
             to the study antibiotic.&#xD;
&#xD;
         17. Patient receiving hemodialysis or peritoneal dialysis.&#xD;
&#xD;
         18. Patient has a history of acute hepatitis in the recent past (3 months prior to study&#xD;
             entry), chronic hepatitis, cirrhosis, acute hepatic failure, or acute decompensation&#xD;
             of chronic hepatic failure.&#xD;
&#xD;
         19. Patient has past or current history of epilepsy or seizure disorders excluding febrile&#xD;
             seizures of childhood.&#xD;
&#xD;
         20. Patient immunocompromised as evidenced by any of the following:&#xD;
&#xD;
               1. Human immunodeficiency virus infection, with either a recent (in the past 6&#xD;
                  months) acquired immune deficiency syndrome-defining condition or a CD4 + T&#xD;
                  lymphocyte count &lt;200/mm3&#xD;
&#xD;
               2. Systemic or hematological malignancy requiring chemotherapeutic or&#xD;
                  radiologic/immunologic interventions within 6 weeks prior to randomization, or&#xD;
                  anticipated to begin prior to completion of study&#xD;
&#xD;
               3. Immunosuppressive therapy, including maintenance corticosteroid therapy (&gt;40&#xD;
                  mg/day equivalent prednisolone) for 5 days or more.&#xD;
&#xD;
         21. Patient participating in any other clinical study that involved the administration of&#xD;
             an investigational medication at the time of presentation, during the course of the&#xD;
             study, or who had received treatment with an investigational medication in the 30 days&#xD;
             prior to study enrollment, or had previously been enrolled in this study or had been&#xD;
             treated with sulopenem.&#xD;
&#xD;
         22. Patient is in a situation or has a condition that, in the investigator's opinion, may&#xD;
             interfere with optimal participation in the study.&#xD;
&#xD;
         23. Patient unlikely to comply with protocol e.g., uncooperative attitude, inability to&#xD;
             return for follow-up visits, and unlikely to complete the study.&#xD;
&#xD;
         24. Patient has known inflammatory bowel disease (ulcerative colitis or Crohn's disease)&#xD;
             or Clostridium difficile-associated diarrhea.&#xD;
&#xD;
         25. Patients with a history of blood dyscrasias&#xD;
&#xD;
         26. Patients with a history of uric acid kidney stones&#xD;
&#xD;
         27. Patients with acute gouty attack&#xD;
&#xD;
         28. Patients on chronic methotrexate therapy&#xD;
&#xD;
         29. Females of child-bearing potential who are unable to take adequate contraceptive&#xD;
             precautions, have a positive pregnancy test result within 24 hours of study entry, are&#xD;
             otherwise known to be pregnant, or are currently breastfeeding an infant.&#xD;
&#xD;
         30. Male subjects who do not agree to use an effective barrier method of contraception&#xD;
             during the study and for 14 days post treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Blagoevgrad</city>
        <zip>2700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Lom</city>
        <zip>3600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Pleven</city>
        <zip>5809</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Plovdiv</city>
        <zip>4003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Plovdiv</city>
        <zip>4004</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Varna</city>
        <zip>9000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Varna</city>
        <zip>9002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Kohtla-Järve</city>
        <zip>31025</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Tallin</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Viljandi</city>
        <zip>71024</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Võru</city>
        <zip>65526</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Gori</city>
        <zip>1400</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Kutaisi</city>
        <zip>4600</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Tbilisi</city>
        <zip>0102</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Tbilisi</city>
        <zip>0114</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Tbilisi</city>
        <zip>0141</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Tbilisi</city>
        <zip>0160</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Veszprém</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Daugavpils</city>
        <zip>5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Riga</city>
        <zip>1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Rēzekne</city>
        <zip>4600</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Bielsk Podlaski</city>
        <zip>17-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Estonia</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2017</study_first_posted>
  <results_first_submitted>October 1, 2020</results_first_submitted>
  <results_first_submitted_qc>November 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 1, 2020</results_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Intraabdominal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Ertapenem</mesh_term>
    <mesh_term>Lactams</mesh_term>
    <mesh_term>Probenecid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03358576/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03358576/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sulopenem</title>
          <description>Sulopenem 1000 mg IV once daily for at least 5 days, followed by Sulopenem-Etzadroxil/Probenecid 500 mg PO twice daily to complete 7-10 days of treatment&#xD;
Sulopenem-Etzadroxil/Probenecid: Antibiotic for complicated intra-abdominal infection&#xD;
Sulopenem: Antibiotic for complicated intra-abdominal infection</description>
        </group>
        <group group_id="P2">
          <title>Ertapenem</title>
          <description>Ertapenem 1000 mg IV once daily for at least 5 days, followed by ciprofloxacin 500 mg PO twice daily along with metronidazole 500 mg PO four times daily. If patient is found to have causative pathogens that are resistant to ciprofloxacin they will receive amoxicillin-clavulanate 875 mg PO twice daily instead&#xD;
Ertapenem: Antibiotic for complicated intra-abdominal infection&#xD;
Ciprofloxacin: Antibiotic for complicated intra-abdominal infection&#xD;
Metronidazole: Antibiotic for complicated intra-abdominal infection&#xD;
Amoxicillin-Clavulanate: Antibiotic for complicated intra-abdominal infection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="338"/>
                <participants group_id="P2" count="336"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="312"/>
                <participants group_id="P2" count="311"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>complicated intra-abdominal infections</population>
      <group_list>
        <group group_id="B1">
          <title>Sulopenem</title>
          <description>Sulopenem 1000 mg IV once daily for at least 5 days, followed by Sulopenem-Etzadroxil/Probenecid 500 mg PO twice daily to complete 7-10 days of treatment&#xD;
Sulopenem-Etzadroxil/Probenecid: Antibiotic for complicated intra-abdominal infection&#xD;
Sulopenem: Antibiotic for complicated intra-abdominal infection</description>
        </group>
        <group group_id="B2">
          <title>Ertapenem</title>
          <description>Ertapenem 1000 mg IV once daily for at least 5 days, followed by ciprofloxacin 500 mg PO twice daily along with metronidazole 500 mg PO four times daily. If patient is found to have causative pathogens that are resistant to ciprofloxacin they will receive amoxicillin-clavulanate 875 mg PO twice daily instead&#xD;
Ertapenem: Antibiotic for complicated intra-abdominal infection&#xD;
Ciprofloxacin: Antibiotic for complicated intra-abdominal infection&#xD;
Metronidazole: Antibiotic for complicated intra-abdominal infection&#xD;
Amoxicillin-Clavulanate: Antibiotic for complicated intra-abdominal infection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="338"/>
            <count group_id="B2" value="336"/>
            <count group_id="B3" value="674"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="443"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="18.4"/>
                    <measurement group_id="B2" value="54.8" spread="18.0"/>
                    <measurement group_id="B3" value="54.3" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="155"/>
                    <measurement group_id="B3" value="315"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="329"/>
                    <measurement group_id="B2" value="328"/>
                    <measurement group_id="B3" value="657"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>creatinine clearance</title>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.7" spread="41.4"/>
                    <measurement group_id="B2" value="87.9" spread="39.1"/>
                    <measurement group_id="B3" value="90.3" spread="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Clinical Success</title>
        <description>Clinical response is defined as resolution in signs and symptoms of the index infection and no new symptoms, without the need for additional antibiotics or interventions</description>
        <time_frame>Day 28 +/- 1 day</time_frame>
        <population>micro-MITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Sulopenem</title>
            <description>Sulopenem 1000 mg IV once daily for at least 5 days, followed by Sulopenem-Etzadroxil/Probenecid 500 mg PO twice daily to complete 7-10 days of treatment&#xD;
Sulopenem-Etzadroxil/Probenecid: Antibiotic for complicated intra-abdominal infection&#xD;
Sulopenem: Antibiotic for complicated intra-abdominal infection</description>
          </group>
          <group group_id="O2">
            <title>Ertapenem</title>
            <description>Ertapenem 1000 mg IV once daily for at least 5 days, followed by ciprofloxacin 500 mg PO twice daily along with metronidazole 500 mg PO four times daily. If patient is found to have causative pathogens that are resistant to ciprofloxacin they will receive amoxicillin-clavulanate 875 mg PO twice daily instead&#xD;
Ertapenem: Antibiotic for complicated intra-abdominal infection&#xD;
Ciprofloxacin: Antibiotic for complicated intra-abdominal infection&#xD;
Metronidazole: Antibiotic for complicated intra-abdominal infection&#xD;
Amoxicillin-Clavulanate: Antibiotic for complicated intra-abdominal infection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Success</title>
          <description>Clinical response is defined as resolution in signs and symptoms of the index infection and no new symptoms, without the need for additional antibiotics or interventions</description>
          <population>micro-MITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5"/>
                    <measurement group_id="O2" value="90.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Success</title>
        <description>Clinical response is defined as resolution in signs and symptoms of the index infection and no new symptoms, without the need for additional antibiotics or interventions</description>
        <time_frame>Day 11-14 +/- 1 day</time_frame>
        <population>micro-MITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Sulopenem</title>
            <description>Sulopenem 1000 mg IV once daily for at least 5 days, followed by Sulopenem-Etzadroxil/Probenecid 500 mg PO twice daily to complete 7-10 days of treatment&#xD;
Sulopenem-Etzadroxil/Probenecid: Antibiotic for complicated intra-abdominal infection&#xD;
Sulopenem: Antibiotic for complicated intra-abdominal infection</description>
          </group>
          <group group_id="O2">
            <title>Ertapenem</title>
            <description>Ertapenem 1000 mg IV once daily for at least 5 days, followed by ciprofloxacin 500 mg PO twice daily along with metronidazole 500 mg PO four times daily. If patient is found to have causative pathogens that are resistant to ciprofloxacin they will receive amoxicillin-clavulanate 875 mg PO twice daily instead&#xD;
Ertapenem: Antibiotic for complicated intra-abdominal infection&#xD;
Ciprofloxacin: Antibiotic for complicated intra-abdominal infection&#xD;
Metronidazole: Antibiotic for complicated intra-abdominal infection&#xD;
Amoxicillin-Clavulanate: Antibiotic for complicated intra-abdominal infection</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Success</title>
          <description>Clinical response is defined as resolution in signs and symptoms of the index infection and no new symptoms, without the need for additional antibiotics or interventions</description>
          <population>micro-MITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="249"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the time of informed consent through the test-of-cure visit, an average of 28 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sulopenem</title>
          <description>Sulopenem 1000 mg IV once daily for at least 5 days, followed by Sulopenem-Etzadroxil/Probenecid 500 mg PO twice daily to complete 7-10 days of treatment&#xD;
Sulopenem-Etzadroxil/Probenecid: Antibiotic for complicated intra-abdominal infection&#xD;
Sulopenem: Antibiotic for complicated intra-abdominal infection</description>
        </group>
        <group group_id="E2">
          <title>Ertapenem</title>
          <description>Ertapenem 1000 mg IV once daily for at least 5 days, followed by ciprofloxacin 500 mg PO twice daily along with metronidazole 500 mg PO four times daily. If patient is found to have causative pathogens that are resistant to ciprofloxacin they will receive amoxicillin-clavulanate 875 mg PO twice daily instead&#xD;
Ertapenem: Antibiotic for complicated intra-abdominal infection&#xD;
Ciprofloxacin: Antibiotic for complicated intra-abdominal infection&#xD;
Metronidazole: Antibiotic for complicated intra-abdominal infection&#xD;
Amoxicillin-Clavulanate: Antibiotic for complicated intra-abdominal infection</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="338"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>ventricular fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>volvulus of small bowel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>intra-abdominal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>small intestine obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>liver abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>appendiceal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>colon gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>colon cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="336"/>
              </event>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>internal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="338"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="336"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="335"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="333"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI will provide manuscripts, abstracts, or full text of any other intended disclosure (poster, invited speaker or guest lecturer, etc) to Iterum at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, the PI agrees to delay disclosure for a period not to exceed an additional 60 days. The PI will, on request, remove any previously undisclosed Confidential Information before disclosure.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director, Clinical Development</name_or_title>
      <organization>Iterum Therapeutics</organization>
      <phone>18606614035</phone>
      <email>saronin@iterumtx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

